Friday, 25 May 2018

You are here

Wear Your Pajamas to Work for Lupus

I suspect that everyone in rheumatology has a special place in their hearts for lupus patients. Their disease is so cruel, and we have so little to offer them, but the young women (and some men) that I treat keep battling on. The longer I have cared for them, the more I wanted to do for them. Managing their illness alone did not seem like enough. 

One of my lupus patients tried to convey to me on several visits just how fatigued and cognitively impaired she would get on her bad days. Finally, to quantify how bad she was feeling, she started telling me how many pajama (PJ) days she was having a week so that I could comprehend how many days she was bedridden due to her illness. 

I started using her catch phrase and asking other patients with SLE how many PJ days they were having per week to asses if I should make a medication change of if they were worse or better with my treatment plan. 

The Lupus Foundation had been emailing me asking for donations. I contacted them on a call with the Rheumatology Nurses Society and pitched my idea to raise money in my clinic by allowing my staff to wear PJs for a $20 donation to the Lupus Foundation on a designated “PJ Day” during Lupus Awareness Month (May).

Several of my colleagues also expressed interest and voila, PJ day was born. I began thinking – “Who wouldn’t like to wear their PJ’s to work? What if every rheumatology clinic across America supported their SLE patients by spending a day in their PJs and donating money to the foundation?”


If you are thinking to yourself “Nice idea Iris, but I work at Mayo, Hopkins, Baylor or Cleveland Clinic and you have no idea what red tape I would have to go through to wear my PJs to work?” fear not! We have you covered!

The Lupus Foundation thought of that too and sell PJ day long sleeve and short sleeve T-shirts which could easily be paired with a lab coat, scrub bottoms, a skirt, worn under a blazer or with a coordinating tie for example. You could even wear a T-shirt over a fancy dress with an amazing pair of shoes (and if you do please send photos to me!). 

So, NO EXCUSES! PJ day is May 2nd, but your office can raise funds anytime in May (especially when the office manager is unaware that the staff has come in wearing PJs.) Last year my little community-based clinic located 30 min away from Flint Michigan raised $1200 for the Lupus Foundation. 

I challenge you all. This is for a good cause. And it’s fun. Click here to donate or join the event:


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

MPO Antibodies Predict Relapses in MPO-ANCA-Associated Vasculitis

A study of MPO-ANCA positive patients followed serially over 2 years shows that reappearance of MPO‐ANCA may predict  relapse in patients with MPO‐ANCA positive AAV and that routine MPO‐ANCA monitoring is warranted. 

This study aimed to establish a potential link between myeloperoxidase (MPO)‐antineutrophil cytoplasmic antibody (ANCA) and relapse in those with ANCA‐associated vasculitis (AAV). 

Severity of Lupus Nephritis is Declining over Time

A retrospective follow-up study of 499 lupus nephritis (LN) patients over three successive eras shows that LN has become less severe in recent years and thus, better long-term survival is possible.

Mortality Risks Shift in Granulomatosis with Polyangiitis

Mortality remains high in granulomatosis with polyangiitis (GPA), but the causes of death tend to change over time, a researcher reported here.

During the first year after diagnosis of GPA, the most common cause of death is active vasculitis, according to Fiona A. Pearce, MBBS, of the University of Nottingham.

Fixed and Tailored Rituximab Regimens Equal in ANCA Associated Vasculitis

The French Vasculitis Study Group has published the results of the MAINRITSAN2 trial designed to  compare individually tailored versus fixed-schedule rituximab (RTX) reinfusion for remission maintenance in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs). 

Lupus Subgroup Responds to Anti-CD22

The monoclonal antibody epratuzumab showed promise as a B-cell depleting agent in patients with concomitant systemic lupus erythematosus (SLE) and Sjogren's syndrome, a post-hoc analysis of two phase III trials found.